Engineering antigen-specific immunological tolerance

Stephan Kontos, Alizée J. Grimm, Jeffrey A. Hubbell

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Unwanted immunity develops in response to many protein drugs, in autoimmunity, in allergy, and in transplantation. Approaches to induce immunological tolerance aim to either prevent these responses or reverse them after they have already taken place. We present here recent developments in approaches, based on engineered peptides, proteins and biomaterials, that harness mechanisms of peripheral tolerance both prophylactically and therapeutically to induce antigen-specific immunological tolerance. These mechanisms are based on responses of B and T lymphocytes to other cells in their immune environment that result in cellular deletion or ignorance to particular antigens, or in development of active immune regulatory responses. Several of these approaches are moving toward clinical development, and some are already in early stages of clinical testing.

Original languageEnglish (US)
Pages (from-to)80-88
Number of pages9
JournalCurrent Opinion in Immunology
Volume35
DOIs
StatePublished - Aug 1 2015
Externally publishedYes

Fingerprint

Active Immunity
Peripheral Tolerance
Antigens
Biocompatible Materials
Autoimmunity
Immunity
Hypersensitivity
Proteins
B-Lymphocytes
Transplantation
T-Lymphocytes
Peptides
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Engineering antigen-specific immunological tolerance. / Kontos, Stephan; Grimm, Alizée J.; Hubbell, Jeffrey A.

In: Current Opinion in Immunology, Vol. 35, 01.08.2015, p. 80-88.

Research output: Contribution to journalArticle

Kontos, Stephan ; Grimm, Alizée J. ; Hubbell, Jeffrey A. / Engineering antigen-specific immunological tolerance. In: Current Opinion in Immunology. 2015 ; Vol. 35. pp. 80-88.
@article{b02ea091b529477dbd1895db37a0ac7f,
title = "Engineering antigen-specific immunological tolerance",
abstract = "Unwanted immunity develops in response to many protein drugs, in autoimmunity, in allergy, and in transplantation. Approaches to induce immunological tolerance aim to either prevent these responses or reverse them after they have already taken place. We present here recent developments in approaches, based on engineered peptides, proteins and biomaterials, that harness mechanisms of peripheral tolerance both prophylactically and therapeutically to induce antigen-specific immunological tolerance. These mechanisms are based on responses of B and T lymphocytes to other cells in their immune environment that result in cellular deletion or ignorance to particular antigens, or in development of active immune regulatory responses. Several of these approaches are moving toward clinical development, and some are already in early stages of clinical testing.",
author = "Stephan Kontos and Grimm, {Aliz{\'e}e J.} and Hubbell, {Jeffrey A.}",
year = "2015",
month = "8",
day = "1",
doi = "10.1016/j.coi.2015.05.005",
language = "English (US)",
volume = "35",
pages = "80--88",
journal = "Current Opinion in Immunology",
issn = "0952-7915",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Engineering antigen-specific immunological tolerance

AU - Kontos, Stephan

AU - Grimm, Alizée J.

AU - Hubbell, Jeffrey A.

PY - 2015/8/1

Y1 - 2015/8/1

N2 - Unwanted immunity develops in response to many protein drugs, in autoimmunity, in allergy, and in transplantation. Approaches to induce immunological tolerance aim to either prevent these responses or reverse them after they have already taken place. We present here recent developments in approaches, based on engineered peptides, proteins and biomaterials, that harness mechanisms of peripheral tolerance both prophylactically and therapeutically to induce antigen-specific immunological tolerance. These mechanisms are based on responses of B and T lymphocytes to other cells in their immune environment that result in cellular deletion or ignorance to particular antigens, or in development of active immune regulatory responses. Several of these approaches are moving toward clinical development, and some are already in early stages of clinical testing.

AB - Unwanted immunity develops in response to many protein drugs, in autoimmunity, in allergy, and in transplantation. Approaches to induce immunological tolerance aim to either prevent these responses or reverse them after they have already taken place. We present here recent developments in approaches, based on engineered peptides, proteins and biomaterials, that harness mechanisms of peripheral tolerance both prophylactically and therapeutically to induce antigen-specific immunological tolerance. These mechanisms are based on responses of B and T lymphocytes to other cells in their immune environment that result in cellular deletion or ignorance to particular antigens, or in development of active immune regulatory responses. Several of these approaches are moving toward clinical development, and some are already in early stages of clinical testing.

UR - http://www.scopus.com/inward/record.url?scp=84936797290&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84936797290&partnerID=8YFLogxK

U2 - 10.1016/j.coi.2015.05.005

DO - 10.1016/j.coi.2015.05.005

M3 - Article

VL - 35

SP - 80

EP - 88

JO - Current Opinion in Immunology

JF - Current Opinion in Immunology

SN - 0952-7915

ER -